IMO the bears and over critical posters here have it wrong. The focus on delays is leading many to believe we will never accomplish anything and if we do accomplish, it will be too late. Let’s review where we are at this point in time.
While there continues to be delays the reality is the milestones are being compressed as the work behind the scene continues to progress. This sets the stage for an onslaught of positive news. We may very well be entering a time in which the value of Leronlimab can no longer be ignored because FDA approval is certain and the data for Mono is just to overwhelming - not to mention the potential Cancer indications.
From my perspective Mono is a slam dunk and BP knows it. Their hope is that our financial constraints and the FDA gauntlet can string us along. That is a big gamble if we get the needed financing. We may have to give a chunk of equity away on a deal that pushes the envelope on the current HIV space. My message to Nader is do whatever it takes in the next couple months to get $50M in the coffers and accelerate the trials.
In regards to the Tender Offer it was interpreted as a failure. I thought they would get 40% participation and instead the number was 20%. After thinking this through did we really think the professional warrant driven Paulson investors would risk anything? They are ZERO risk, sell all shares, hold their warrants investors. They don’t deviate and have kept the lid on the SP for years. Many financing deals are in the works and if successful the door will close on future access to ANY new warrants allowing the SP to represent the real valuation of Leronlimab. This along with a continual stream of positive news is the perfect storm.
The negative focus on Nader is wasted energy as he will not be replaced. He has his strengths and weaknesses but he knows more about Leronlimab from more angles than anyone on the face of this planet. Kelly and the BOD will continue to bring in talent that lessens Nader’s responsibilities in areas of weakness. This is a necessary move as we take this home.
From my perspective we are approaching the best of times.
Market Data 
Markets 
AI
